Neuphoria Therapeutics Inc. has 11 Schedule 13D or 13G filings on record since 2025-10-23. 2 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 Lynx1 Capital Management LP
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On December 2, 2025, the Reporting Persons delivered a letter to the Board which contained a new non-binding proposal (the "Recalculated Initial Offer") to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, all of the outstanding shares of capital stock of the Company for a price of $4.75 per share in cash.From Item 4 of the SCHEDULE 13D/A filed 2025-12-02
Intent stated in Item 4 Lynx1 Capital Management LP
On November 10, 2025, the Reporting Persons delivered a letter to the Board which contained a non-binding proposal (the "Proposal") to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, all of the outstanding shares of capital stock of the Company for a price of $5.20 per share in cash (the "Proposed Transaction"), which represents a premium of approximately 27% over the $4.10 closing stock price of the Company's Common Stock on the Nasdaq on November 7, 2025, the last full trading day prior to the submission of the Proposal.From Item 4 of the SCHEDULE 13D/A filed 2025-11-10
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 16.3% | 875,328 | SCHEDULE 13D/A, 2025-12-29 | 2025-12-26 |
| Shay Capital LLC | 7.3% | 171,629 | SCHEDULE 13G, 2025-10-31 | 2025-10-24 |
| Coastlands Capital LP | 4.23% | 228,594 | SCHEDULE 13G/A, 2026-07-28 | 2026-07-23 |
| Baselake Partners, LP | 4.1% | 222,222 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 |
Purpose of Transaction (Item 4)
Lynx1 Capital Management LP
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On December 26, 2025, the Reporting Persons made an offer to the Board to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, certain intellectual-property-related assets of the Company in an all-cash transaction, or if the Company prefers, through the delivery by the Reporting Persons to the Company of shares of Common Stock of the Company with equivalent value (the "IP Rights Proposal"). The IP Rights Proposal is subject to the Reporting Persons' due diligence and agreement on definitive documentation for the acquisition. Neither the Reporting Persons nor the Company is obligated to complete a transaction in connection with the IP Rights Proposal, and there can be no assurance (i) as to the outcome of any discussions related to the IP Rights Proposal; (ii) that any agreement will be reached between the Company and the Reporting Persons; (iii) that the terms of any transaction will not differ from the terms contemplated by the IP Rights Proposal; or (iv) that the Reporting Persons will not from time to time make offers for other assets of the Company. The IP Rights Proposal may result in one or more of the actions specified in clauses (a)-(j) of Item 4 of Schedule 13D, including the disposition of securities of the Company and/or a sale or transfer of a material amount of the Company's assets. The Reporting Persons may further consider …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-29; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-23 | Lynx1 Capital Management LP | 37.1% | SCHEDULE 13D |
| 2025-10-31 | Shay Capital LLC | 7.3% | SCHEDULE 13G |
| 2025-10-31 | Baselake Partners, LP | 9.4% | SCHEDULE 13G |
| 2025-11-05 | Coastlands Capital LP | 5.1% | SCHEDULE 13G |
| 2025-11-10 | Lynx1 Capital Management LP intent stated | 26.5% | SCHEDULE 13D/A |
| 2025-11-18 | Lynx1 Capital Management LP | 16.3% | SCHEDULE 13D/A |
| 2025-11-28 | Lynx1 Capital Management LP | 16.3% | SCHEDULE 13D/A |
| 2025-12-02 | Lynx1 Capital Management LP intent stated | 16.3% | SCHEDULE 13D/A |
| 2025-12-29 | Lynx1 Capital Management LP | 16.3% | SCHEDULE 13D/A |
| 2026-02-06 | Baselake Partners, LP | 4.1% | SCHEDULE 13G/A |
| 2026-07-28 | Coastlands Capital LP | 4.23% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Neuphoria Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.